Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment

Jiang, 2015, The past, present and future of immunotherapy against tumor, Transl. Lung Cancer Res., 4, 253 Makkouk, 2015, Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge, Cancer Res., 75, 5, 10.1158/0008-5472.CAN-14-2538 Wen, 2013, Retaining antibodies in tumors with a self-assembling injectable system, Mol. Pharm., 10, 1035, 10.1021/mp300504z Rini, 2014, Future approaches in immunotherapy, Semin. Oncol., 41, S30, 10.1053/j.seminoncol.2014.09.005 Wen, 2015, Supramolecular peptide vaccines: tuning adaptive immunity, Curr. Opin. Immunol., 35, 73, 10.1016/j.coi.2015.06.007 Robinette, 2014, Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies, Vaccine, 32, 375, 10.1016/j.vaccine.2013.11.023 Chia, 2014, Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma, Mol. Ther. J. Am. Soc. Gene Ther., 22, 132, 10.1038/mt.2013.242 Niezgoda, 2015, Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy, Biomed. Res. Int., 2015, 851387, 10.1155/2015/851387 Johansson, 2015, More than a scaffold: stromal modulation of tumor immunity, Biochim. Biophys. Acta, 1865, 3 Becker, 2013, Immune-suppressive properties of the tumor microenvironment, Cancer Immunol. Immunother. CII, 62, 1137, 10.1007/s00262-013-1434-6 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703 Kerkar, 2012, Cellular constituents of immune escape within the tumor microenvironment, Cancer Res., 72, 3125, 10.1158/0008-5472.CAN-11-4094 Devaud, 2013, Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy, Oncoimmunology, 2, 10.4161/onci.25961 Blumenthal, 2012, FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors, Oncologist, 17, 1108, 10.1634/theoncologist.2012-0044 Chinchar, 2014, Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells, Vasc. Cell, 6, 12, 10.1186/2045-824X-6-12 Jaini, 2014, Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy, Int. J. Cancer, 134, 1695, 10.1002/ijc.28488 Farsaci, 2012, Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy, Int. J. Cancer, 130, 1948, 10.1002/ijc.26219 Draghiciu, 2015, Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication, Oncoimmunology, 4, 10.4161/2162402X.2014.989764 Ozao-Choy, 2009, The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies, Cancer Res., 69, 2514, 10.1158/0008-5472.CAN-08-4709 Xu, 2014, Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment, ACS Nano, 8, 3636, 10.1021/nn500216y Xu, 2013, Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis, J. Control. Release: Off. J. Control. Release Soc., 172, 259, 10.1016/j.jconrel.2013.08.021 Guo, 2014, Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation, ACS Nano, 8, 4996, 10.1021/nn5010815 Yin, 2015, Well-defined redox-sensitive polyethene glycol-paclitaxel prodrug conjugate for tumor-specific delivery of paclitaxel using octreotide for tumor targeting, Mol. Pharm., 12, 3020, 10.1021/acs.molpharmaceut.5b00280 Castillo-Avila, 2009, Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 15, 3384, 10.1158/1078-0432.CCR-08-2170 Waterhouse, 1997, Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models, Nucl. Med. Biol., 24, 587, 10.1016/S0969-8051(97)00030-9 Website: http://www.eurodiagnostico.com/media/pdf/Sunitinib%20Malate%20(Sutent).pdf. Saha, 2010, Nanoparticulate drug delivery systems for cancer chemotherapy, Mol. Membr. Biol., 27, 215, 10.3109/09687688.2010.510804 Yin, 2015, Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer, Biomaterials, 61, 10, 10.1016/j.biomaterials.2015.05.022 Farsaci, 2014, Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines, Cancer Immunol. Res., 2, 1090, 10.1158/2326-6066.CIR-14-0076 Bose, 2011, Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination, Int. J. Cancer, 129, 2158, 10.1002/ijc.25863 Kaiserman, 2004, Liver function tests in metastatic uveal melanoma, Am J. Ophthalmol., 137, 236, 10.1016/j.ajo.2003.08.045 Lindau, 2013, The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells, Immunology, 138, 105, 10.1111/imm.12036 Takehara, 2013, Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma, Clin. Immunol., 149, 1, 10.1016/j.clim.2013.05.019 Bendle, 2005, Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy, Expert. Opin. Biol. Ther., 5, 1183, 10.1517/14712598.5.9.1183 Nishioka, 2010, Role of tyrosine kinase inhibitors in tumor immunology, Immunotherapy, 3, 107, 10.2217/imt.10.79 van Cruijsen, 2008, Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 14, 5884, 10.1158/1078-0432.CCR-08-0656 Xin, 2009, Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells, Cancer Res., 69, 2506, 10.1158/0008-5472.CAN-08-4323 Ko, 2009, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 15, 2148, 10.1158/1078-0432.CCR-08-1332 Shurin, 1999, Th1/Th2 balance in cancer, transplantation and pregnancy, Springer Semin. Immunopathol., 21, 339, 10.1007/BF00812261 Zhang, 2015, The dual-functional capability of cytokine-induced killer cells and application in tumor immunology, Hum. Immunol., 76, 385, 10.1016/j.humimm.2014.09.021 Jones, 2002, Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL), Leuk. Lymphoma, 43, 1313, 10.1080/10428190290026385 Wongkajornsilp, 2013, Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells, PLoS One, 8, 10.1371/journal.pone.0078980 Barik, 2013, Neem leaf glycoprotein is superior than cisplatin and sunitinib malate in restricting melanoma growth by normalization of tumor microenvironment, Int. Immunopharmacol., 17, 42, 10.1016/j.intimp.2013.05.005 Finke, 2008, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., 14, 6674, 10.1158/1078-0432.CCR-07-5212 Ghiringhelli, 2005, Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation, J. Exp. Med., 202, 919, 10.1084/jem.20050463 Krock, 2011, Hypoxia-induced angiogenesis: good and evil, Genes Cancer, 2, 1117, 10.1177/1947601911423654 Oelkrug, 2014, Enhancement of T cell recruitment and infiltration into tumours, Clin. Exp. Immunol., 178, 1, 10.1111/cei.12382 Bellone, 2013, Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes, Front. Oncol., 3, 231, 10.3389/fonc.2013.00231 Zhou, 2015, Perspective of targeting cancer-associated fibroblasts in melanoma, J. Cancer, 6, 717, 10.7150/jca.10865 Rygiel, 2011, Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1, Mol. Immunol., 49, 402, 10.1016/j.molimm.2011.09.006 Guo, 2014, Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation, ACS Nano, 8, 4996, 10.1021/nn5010815 Zhang, 2014, Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model, J. Control. Release: Off. J. Control. Release Soc., 182, 90, 10.1016/j.jconrel.2014.03.016 Al Zaid Siddiquee, 2008, STAT3 as a target for inducing apoptosis in solid and hematological tumors, Cell Res., 18, 254, 10.1038/cr.2008.18 Kida, 2013, Involvement of STAT3 in immune evasion during lung tumorigenesis, Oncoimmunology, 2, 10.4161/onci.22653 Rebe, 2013, STAT3 activation: a key factor in tumor immunoescape, Jak-Stat, 2, 10.4161/jkst.23010 Yang, 2015, Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model, Cell Death Dis., 6, 10.1038/cddis.2015.63 Noh, 2009, Activation of Akt as a mechanism for tumor immune evasion, Mol. Ther.: J. Am. Soc. Gene Ther., 17, 439, 10.1038/mt.2008.255